Skip to main content

and
  1. Article

    Open Access

    Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

    Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chem...

    Colin R. Lindsay, Emily C. Shaw, David A. Moore, Doris Rassl in British Journal of Cancer (2021)

  2. Article

    Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

    Francesca Chemi, Dominic G. Rothwell, Nicholas McGranahan, Sakshi Gulati in Nature Medicine (2020)

  3. No Access

    Article

    Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

    Approximately 50% of patients with early-stage non-small-cell lung cancer (NSCLC) who undergo surgery with curative intent will relapse within 5 years1,2. Detection of circulating tumor cells (CTCs) at the time o...

    Francesca Chemi, Dominic G. Rothwell, Nicholas McGranahan, Sakshi Gulati in Nature Medicine (2019)

  4. Article

    Open Access

    SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting

    We investigated selumetinib (AZD6244, ARRY-142886), an oral, potent, and highly selective, allosteric MEK1/2 inhibitor, plus platinum-doublet chemotherapy for patients with advanced/metastatic non-small cell l...

    Alastair Greystoke, Nicola Steele, Hendrik-Tobias Arkenau in British Journal of Cancer (2017)